On the other hand, sustained, i.e. chronic, IFN activation can be highly detrimental in cancer, especially contributing to CD8+ T cell exhaustion (21), a process marked by progressive loss of effector functions and insensitivity to therapeutic immune checkpoint inhibitors (ICI) (22). The gene discussed is IFNA1; the disease is cancer.